News & Updates

A surgical intervention performed for inflammatory bowel disease (IBD) appears to confer favourable effects on patient-reported outcomes such as pain and overall health, according to a prospective, longitudinal cohort study.

In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

A high diet quality characterized by increased intake of fish and vegetables and limited consumption of sugary drinks at 1 year of age appears to offer protection against subsequent inflammatory bowel disease (IBD), as reported in a study.